Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Auscann Group Holdings Ltd ACNNF

Healthcare
AusCann Group Holdings Limited is an Australia-based company focused on the development and commercialization of cannabinoid-derived therapeutic products to address unmet needs for humans and animals within Australia and internationally. It has launched tetrahydrocannabinol and cannabidiol (THC/CBD) powder-based hard-shell capsules, based on the Company’s Neuvis platform, for the treatment of pain and related indications. Its products include CPAT-01, DermaCann and MicroMax. CPAT-01 is a liquid, oral veterinary medicine containing standardized tetrahydrocannabinol (THC) and cannabinoids (CBD) whole plant extracts in a proprietary ratio to target pain and inflammation in dogs. DermaCann is a CBD-derived nutraceutical in development for healthy skin and immune function in dogs with dermatological conditions. The product is a liquid oral oil formulation containing CBD in a patented combination with other bioactive lipids designed to target inflammation and immune modulation pathways.


OTCPK:ACNNF - Post by User

Auscann Group Holdings Ltd
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(19)
•••
Post by Bullognaon Dec 12, 2017 6:17pm
181 Views
Post# 27142372

Patience

PatienceIs the plan, we may be a little early for the party down under, and I could care less if it drops, I'm in after watching since it first came out and not buying and not buying the last dip either.. grr.   Oh well I'm in.  I will not look at this stock until 2021, by then I hope I will be as pleased with where it is then as I am with canopy and Aphria.   that is the potential here, even half what they are will be great.   the dominos are falling, legalization will follow, patience is required.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities